Journal of Blood & Lymph

Background: Personality trait is a complex trait of an individual, which has been hypothesized to have link with diseases. It is believed that understanding personality traits of an individual can assist to prevent the diseases. Therefore, scientists are trying to explore potential factors that can predict the personality traits of an individual. Blood groups could be a potential predictor because some researchers have found a linkage between ABO genes and genes related to the development of personality traits in someone. Few studies have already found a significant relationship between blood groups and personality traits. However, there is still a paucity of researches to reach out a conclusion on this topic. Our study is another attempt to find out the possible relationship between blood groups and personality traits.

Method: The present study was a cross-sectional study which used a 50 items big-five factor personality inventory developed by Goldberg for data collection. A total of 148 participants responded to the study among them 85 participants were males and 65 were females. A two way multivariate analysis (MANOVA) was performed using IBM SPSS Statistics version 26.

Result: MANOVA results revealed neither the significant main effect of blood groups [F (15,414)=1.102, p>0.05] nor had the significant interaction effect of blood groups and gender [F (15,414)=1.111, p>0.05] on the combined dependent variables. However, this study found a significant main effect of gender on the combined dependent variables [F (5,136)=4.520, p=0.001, (1-β)=0.967, η2=0.143].

Conclusion: The present study did not support the idea that there is significant relationship between blood groups and personality traits. But, the idea that male personality significantly differs from female personality was well-supported by this study.

Background: The Prognostic Nutritional Index (PNI), a valuable parameter for predicting short-term and long-term postoperative outcomes in patients undergoing cancer surgery, is calculated based on serum albumin concentration and peripheral blood lymphocyte count. However, few studies have investigated the clinical significance of PNI in the surgical treatment of colorectal cancer. Therefore, we aimed to examine the relationship between PNI and short-term outcomes in patients with colorectal cancer.

Methods: This retrospective study included 328 patients who underwent surgery for colorectal cancer. The prognostic nutritional status was calculated based on admission data as follows: 10* serum albumin (g/dl)+0.005* total lymphocyte count (per mm3). Then we evaluated the relationship between PNI value and postoperative complications in colorectal cancer patients.

Results: Patients with low PNI (<35.3) had a significantly higher rate of postoperative complications (p<0.05) than those with a high PNI (≥35.3). In Univariate analysis low PNI (p=0.015), open surgical approach (p=0.010), tumor location (p=0.008), N stage ≥ 2 (p=0.037), serum albumin concentration (p=0.015) and CEA level ≥ 5 (p=0.017) were significantly associated with high complications rate. However, in multivariate analyses, low preoperative PNI was not identified as an independent factor for postoperative complications.

Conclusion: Preoperative PNI is a valuable marker for postoperative complications in patients with colorectal cancer.

Reasoning: Movement of Persistent Myelogenous Leukemia (CML) to further developed stages can include hypermethylation, which is connected to opposition or prejudice to imatinib. This hypermethylation has likewise been viewed as a negative prognostic component free of imatinib reaction and from CML stage, consequently decitabine, a hypomethylating specialist, can be an appealing treatment choice for cutting edge stage CML.

Objective: This foundational survey and meta-examination expects to research the job of low-portion decitabine among patients with cutting edge stage CML. Technique: This was performed by the articulation of Favored Announcing Things for Orderly Surveys and Meta-Examinations (PRISMA).

Results: Four (4) studies from 86 articles screened were qualified to be evaluated in this fundamental audit and meta-investigation. These were stage I/II preliminaries including 81 high level stage CML patients and utilized low-portion decitabine (5 to 20 mg/m²), with two examinations utilizing tyrosine kinase inhibitors.

Results of hematologic and cytogenetic reaction, and endurance were evaluated in the meta-examination; with hematologic reaction being leaned toward among cutting edge stage CML patients upon openness with low-portion decitabine (p=0.05). Endurance was likewise preferred among responders to low-portion decitabine, but this was not huge.

Conversation and end: Low-portion decitabine can be a compelling and safe therapy choice in cutting edge stage CML, particularly in additional fragile patients that couldn't endure more escalated chemotherapy regimens.

Notwithstanding, this study is restricted by couple of studies accessible on this point, subsequently further randomized controlled preliminaries can be explored to characterize the job of decitabine and its ideal portion among this subset of patients